Likewise, CD5+ MZL has been shown to have higher rates of transformation to diffuse large B-cell lymphoma and have lower response rates (30% vs. 77%), PFS (25% vs. 45% at 3 years), and OS (44% vs. 77%) to rituximab compared to their CD5- counterparts [32]. Here, CD5 is linked to diffuse large B-cell lymphoma.